---
title: "NBIX: Strong Crenessity and Ingrezza Outperformance, Robust 2026 Outlook and Pipeline Catalysts Underpin Buy Rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285267932.md"
description: "William Blair analyst Myles Minter has maintained a Buy rating on NBIX stock, citing strong revenue performance from Crenessity and Ingrezza. He notes that Crenessity's launch is exceeding expectations and that Ingrezza has surpassed forecasts. Minter emphasizes the company's robust 2026 sales guidance and highlights upcoming catalysts, including the Soleno acquisition and the advancement of NBI-1117570 into Phase II. Needham also supports a Buy rating for the stock."
datetime: "2026-05-05T20:55:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285267932.md)
  - [en](https://longbridge.com/en/news/285267932.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285267932.md)
---

# NBIX: Strong Crenessity and Ingrezza Outperformance, Robust 2026 Outlook and Pipeline Catalysts Underpin Buy Rating

William Blair analyst Myles Minter has maintained their bullish stance on NBIX stock, giving a Buy rating on April 24.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Myles Minter has given his Buy rating due to a combination of factors, including stronger-than-expected revenue performance from both Crenessity and Ingrezza in the first quarter. He views the Crenessity launch in CAH as tracking ahead of expectations, with additional upside as new patient additions normalize and the enlarged sales team that began in April gains traction.

Minter also highlights that Ingrezza materially exceeded internal and Street forecasts, while management reaffirmed robust full-year 2026 sales and expense guidance, signaling confidence in the underlying business. He further points to the pending Soleno acquisition and the advancement of the M1/M4 agonist NBI-1117570 into Phase II as catalysts that should broaden the high-growth portfolio and support durable top-line expansion, reinforcing his positive stance on NBIX shares.

In another report released on April 24, Needham also maintained a Buy rating on the stock with a $0.00 price target.

### Related Stocks

- [NBIX.US](https://longbridge.com/en/quote/NBIX.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SLNO.US](https://longbridge.com/en/quote/SLNO.US.md)

## Related News & Research

- [Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors](https://longbridge.com/en/news/286946226.md)
- [Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal](https://longbridge.com/en/news/286873474.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)